A5057532121- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Monoclonal and Polyclonal Antibodies Research
- Cancer Mechanisms and Therapy
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Cell Adhesion Molecules Research
- Cancer Genomics and Diagnostics
- FOXO transcription factor regulation
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Neurofibromatosis and Schwannoma Cases
- Mechanisms of cancer metastasis
- BRCA gene mutations in cancer
Yeungnam University
2016-2024
Yeungnam University College
2016-2024
Oncotype DX (ODX) is a well-validated multigene assay that increasingly used in Korean clinical practice. This study aimed to develop clinicopathological prediction (CPP) model for the ODX recurrence scores (RSs).A total of 297 patients (study group, n = 175; external validation 122) with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, T1-3N0-1M0 breast cancer, and available test results were included study. Risk categorization as determined by RSs...
Purpose Notable effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer (BC) has focused pathologists’ attention. We studied the incidence and clinicopathologic characteristics HER2-low BC, effects immunohistochemistry (IHC) associated factors on HER2 IHC results.Materials Methods The Breast Pathology Study Group Korean Society Pathologists conducted a nationwide study using real-world data status generated between...
Background: CD9, a member of the tetraspanin superfamily, is tumor suppressor in many malignancies.The aim this study was to evaluate immunohistochemical expression CD9 colorectal carcinomas (CRCs) and determine clinicopathological prognostic significance its expression.Methods: The status 305 CRCs evaluated using semi-quantitative scoring system cells (T-CD9) immune (I-CD9) by classifying results as high low expression.Results: High T-CD9 (T-CD9 [+]) detected 175 samples (57.6%) I-CD9...
The updated American Society of Clinical Oncology/College Pathologists guideline for estrogen receptor (ER) testing recommends that breast cancer with ER expression in 1-10% tumor cells should be reported as ER-low positive (ERlow), although limited data are available on the overall benefits endocrine therapy. We investigated clinicopathological characteristics and clinical outcomes ERlow to compare them those ER-negative (ERneg) ER-high (> 10% cells, ERhigh) cancers.Consecutive patients...
In 2007, the American Society of Clinical Oncology and College Pathologists had established a human epidermal growth factor receptor 2 (HER2) testing guideline, which was updated in 2013 subsequently 2018. We assessed clinical impact recent update by comparing situ hybridization (ISH) results based on 2013, 2018 guidelines.We cohorts. The first cohort included 1,161 primary invasive breast cancer (IBC) samples including 18 bilateral IBC cases, with both immunohistochemistry (IHC)...
Plexiform schwannomas representing a rare subset, comprise 5% of all schwannomas. However, their occurrence in the thyroid gland is exceptionally rare. A 32-year-old male presented with an incidentally discovered, asymptomatic mass. Imaging revealed approximately 5 cm heterogeneous solid mass on right lobe extending to upper mediastinum and directly invading trachea. Under suspicion malignancy, patient underwent thyroidectomy. Histological examination confirmed plexiform schwannoma...